A cross-sectional survey of pain in palliative care in Portugal
- First Online:
- 301 Downloads
The purpose of this work is to study the prevalence, intensity, and treatment of pain in Portuguese palliative care teams.
Twenty-one palliative care teams were invited to participate in a cross-sectional survey. Ten of these accepted and were included in the study. Data of all patients observed on the 18th week of 2011 were collected. The data collected concerning pain were: demographic data, pain intensity, drugs prescribed, and invasive techniques. The intensity of pain was rated using a five-point verbal rating scale from none to maximum. The Pain Management Index (PMI) was used to calculate the adequacy of the analgesia.
A total of 164 patients were included in this study. One hundred fifty-one (92 %) had cancer. The median age was 71 years (16 to 95). Eighty-four (51 %) were females. Pain was directly assessed in 136 (83 %) of the patients, whereas 27 patients could not report pain because of cognitive failure. Of those directly assessed, 77 (57 %) had pain when they were assessed: 42 (55 %) mild, 25 (32 %) moderate, 9 (12 %) severe, and 1 (1 %) maximum. Non-opioid analgesics were used: paracetamol in 61 (37 %) and NSAID in 20 (12 %). Tramadol was the only opioid for mild to moderate pain used in 25 (15 %) patients. The opioids most used for moderate to intense pain were: morphine 74 (45 %), transdermal (TD) fentanyl 32 (20 %), and buprenorphine TD 28 (17 %). The adjuvants most used were: corticosteroids 38 (23 %), gabapentin 37 (23 %), and amitriptyline 15 (9 %). Only five (4 %) patients had a negative PMI, meaning an inadequate analgesia.
The general prevalence of pain is similar to that reported by other. The prevalence of moderate to severe pain is also similar to that reported in other studies, although severe pain is somewhat lower than indicated in most reports. According to the PMI, pain control was acceptable to good.
KeywordsPalliative care Portugal Pain Pain control Pain Management Index
- 13.Hill CS (1993) The barriers to adequate pain management with opioids analgesics. Sem Oncol 20(suppl 1):1–5Google Scholar
- 18.van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437–1449Google Scholar
- 24.Oscier C, Bosley N, Milner Q (2007) Paracetamol—a review of three routes of administration. Updat Anaesth 23:112–114Google Scholar
- 27.http://www.infarmed.pt/prontuario/framepesactivos.php?palavra=dextropropoxifeno&rb1=0. Accessed 20 June 2012
- 29.Ripamonti CI, Banderi E, Roila F (2011) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 22(suppl 6):v257–v260Google Scholar
- 33.Wiffen PJ, Collins S, McQuay HJ, Carroll D, Jadad A, Moore RA (2010) WITHDRAWN. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 20(1):CD001133Google Scholar
- 36.Lussier D, Portenoy RK (2004) Adjuvant analgesics in pain management. In: Doyle D, Hanks G, Cherny N, Calman K (eds) Oxford textbook of palliative medicine, 3rd edn. Oxford University Press, Oxford, pp 349–378Google Scholar